Patients who were dosed with Praxis' vormatrigine over eight weeks experienced a 56.3% median reduction in seizure frequency.

The US FDA has approved Anbogen Therapeutics’ IND application for the oral HDAC1/2/3 inhibitor ABT-301 in preparation for a Phase I/II trial.

For the first time in decades, the pharmaceutical industry has been directly affected by a geopolitical trade negotiation between the US and the EU.

Atavistik Bio has dosed the first subject in its Phase I clinical trial of ATV-1601, designed to treat adults with solid tumours.